ANDATOPICALSOLUTION
Approved
Mar 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
FLUOCINONIDE (fluocinonide) by Gen Pharmaceuticals is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 2019.
Drug data last refreshed 19h ago
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
Started Sep 2011
34 enrolled
Breast Carcinoma
Company
Gen Pharmaceuticals
Worked on FLUOCINONIDE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.